Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2022-05-03 Investor Presentation
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Dermatology Asset Acquired to Accelerate Path to Revenue 35 pages 12.5MB
Investor Presentation Classification · 95% confidence The document is a detailed announcement about Botanix Pharmaceuticals acquiring a dermatology asset, Sofpironium Bromide gel, including clinical data, market potential, and financial terms of the acquisition. It discusses the asset's development stage, regulatory plans (NDA filing expected in 2H 2022), and commercial strategy. The text includes a presentation overview and detailed deal terms but does not contain actual financial statements or quarterly/yearly financial results. It is not a full annual or interim report, nor an earnings release. It is also not a regulatory filing or certification. The document is primarily an investor presentation announcing a significant acquisition and strategic update with detailed information for investors about the asset and the company's plans. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-05-03 English
Botanix Investor Webinar 2 pages 166.1KB
Investor Presentation Classification · 95% confidence The document is an announcement dated 4 May 2022 about an upcoming investor webinar hosted by Botanix Pharmaceuticals. It provides details about the webinar, including date, time, registration link, and speakers. The content focuses on updating shareholders about the acquisition of a product and the company's clinical pipeline. There are no financial statements, detailed financial analysis, or regulatory filings included. The document is essentially an invitation and informational notice about a live event for investors, which fits the definition of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in webinar format. The document length is under 5,000 characters, but it is not merely announcing a report publication or providing a link to a report; it is announcing a live investor event. Therefore, the best classification is Investor Presentation (IP).
2022-05-03 English
Trading Halt 2 pages 176.1KB
Capital/Financing Update Classification · 90% confidence The document is a market announcement from Botanix Pharmaceuticals Ltd regarding a trading halt requested pending an announcement about the acquisition of a dermatology asset. It is a short notice about a trading halt and does not contain financial data, detailed report content, or results. It is an announcement related to capital or financing activity (acquisition), but it is specifically about the trading halt pending the announcement, not the announcement itself or a detailed financing update. Given the nature of the document as a trading halt notice related to an upcoming announcement on acquisition, the best fitting category is Capital/Financing Update (CAP). The document is not a full report, earnings release, or regulatory filing, but a specific update on capital-related activity.
2022-05-02 English
Appendix 4C - Quarterly 9 pages 367.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Botanix Quarterly Activity Report and 4C Quarterly Cash Flow Report' and is dated 29 April 2022, covering the quarter ended 31 March 2022. It contains detailed information about clinical studies, corporate developments including executive appointments, and a financial overview with cash flow statements. The presence of the Appendix 4C Quarterly Cash Flow Report, which is a regulatory requirement for Australian listed companies, confirms this is a quarterly report with substantive financial data and analysis. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2022-04-28 English
FDA Qualified Infectious Disease Product Status for BTX 1801 3 pages 246.6KB
Regulatory Filings Classification · 95% confidence The document is a press release dated 28 April 2022 announcing that the US FDA has granted Botanix Pharmaceuticals a new Qualified Infectious Disease Product (QIDP) designation for its investigational antibacterial product BTX 1801. The content focuses on regulatory approval status, clinical study progress, and the benefits of the QIDP designation such as exclusivity and fast-track status. There are no financial statements, detailed financial performance data, or comprehensive management discussion of financial results. The document is an update on regulatory and clinical development progress rather than a formal financial report or earnings release. It is also not a report publication announcement since it does not mention the release or availability of a report. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA designation and clinical development status that does not fit into other specific categories like earnings release or capital update.
2022-04-27 English
Botanix upcoming presentation - Health Economics Conference 3 pages 278.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing an upcoming presentation by Botanix Pharmaceuticals at the Professional Society for Health Economics and Outcomes Research Annual Meeting (ISPOR 2022). It details the topic of the presentation, the event dates, and some background on the study to be presented. There are no financial statements, regulatory filings, or detailed financial data included. The document is not a report itself but an announcement of a presentation event. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit any other specific category.
2022-04-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.